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Abstract: Introduction: The previously published SYNTAX III REVOLUTION trial demonstrated that
clinical decision-making between coronary artery bypass graft (CABG) and percutaneous coronary in-
tervention based on coronary CT angiography (CCTA) had a very high agreement with the treatment
decision derived from invasive coronary angiography (ICA). The study objective of the FASTTRACK
CABG is to assess the feasibility of CCTA and fractional flow reserve derived from CTA (FFRCT) to
replace ICA as a surgical guidance method for planning and execution of CABG in patients with three-
vessel disease with or without left main disease. Methods and analysis: The FASTTRACK CABG is an
investigator-initiated single-arm, multicentre, prospective, proof-of-concept and first-in-man study with
feasibility and safety analysis. Surgical revascularisation strategy and treatment planning will be solely
based on CCTA and FFRCT without knowledge of the anatomy defined by ICA. Clinical follow-up visit
including CCTA will be performed 30 days after CABG in order to assess graft patency and adequacy of
the revascularisation with respect to the surgical planning based on non-invasive imaging (CCTA) with
functional assessment (FFRCT) and compared with ICA. Primary feasibility endpoint is CABG planning
and execution solely based on CCTA and FFRCT in 114 patients. Primary safety endpoint based on 30
day CCTA is graft assessment and topographical adequacy of the revascularisation procedure. Automatic
non-invasive assessment of functional coronary anatomy complexity is also evaluated with FFRCT for
functional Synergy Between percutaneous coronary intervention With Taxus and Cardiac Surgery Score
assessment on CCTA. CCTA with FFRCT might provide better anatomical and functional analysis of
the coronary circulation leading to appropriate anatomical and functional revascularisation, and thereby
contributing to a better outcome. Ethics and dissemination: Each patient has to provide written informed
consent as approved by the ethical committee of the respective clinical site. Results will be submitted
for publication in peer-reviewed journals and will be disseminated at scientific conferences.
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ABSTRACT
Introduction The previously published SYNTAX III 
REVOLUTION trial demonstrated that clinical decision- 
making between coronary artery bypass graft (CABG) and 
percutaneous coronary intervention based on coronary 
CT angiography (CCTA) had a very high agreement with 
the treatment decision derived from invasive coronary 
angiography (ICA). The study objective of the FASTTRACK 
CABG is to assess the feasibility of CCTA and fractional 
flow reserve derived from CTA (FFR
CT
) to replace ICA as a 
surgical guidance method for planning and execution of 
CABG in patients with three- vessel disease with or without 
left main disease.
Methods and analysis The FASTTRACK CABG is an 
investigator- initiated single- arm, multicentre, prospective, 
proof- of- concept and first- in- man study with feasibility 
and safety analysis. Surgical revascularisation strategy 
and treatment planning will be solely based on CCTA and 
FFR
CT
 without knowledge of the anatomy defined by ICA. 
Clinical follow- up visit including CCTA will be performed 
30 days after CABG in order to assess graft patency 
and adequacy of the revascularisation with respect to 
the surgical planning based on non- invasive imaging 
(CCTA) with functional assessment (FFR
CT
) and compared 
with ICA. Primary feasibility endpoint is CABG planning 
and execution solely based on CCTA and FFR
CT
 in 114 
patients. Primary safety endpoint based on 30 day CCTA 
is graft assessment and topographical adequacy of the 
revascularisation procedure. Automatic non- invasive 
assessment of functional coronary anatomy complexity is 
also evaluated with FFR
CT
 for functional Synergy Between 
percutaneous coronary intervention With Taxus and 
Cardiac Surgery Score assessment on CCTA. CCTA with 
FFR
CT
 might provide better anatomical and functional 
analysis of the coronary circulation leading to appropriate 
anatomical and functional revascularisation, and thereby 
contributing to a better outcome.
Strengths and limitations of this study
 ► The FASTTRACK coronary artery bypass graft (CABG) 
study evaluates the feasibility and safety of planning 
and execution of CABG solely based on CT angiog-
raphy (CCTA) combined with fractional flow reserve 
derived from CTA (FFR
CT
) without knowledge of the 
anatomy defined by invasive coronary angiography.
 ► At 30 days after CABG, postsurgical CCTA is planned 
to evaluate the patency of bypass grafts and 
topographical adequacy of the revascularisation 
procedure.
 ► CCTA with FFR
CT
 might provide better anatomical 
and functional analysis of the coronary circulation 
leading to appropriate anatomical and functional re-
vascularisation, and thereby contributing to a better 
outcome.
 ► The FASTTRACK CABG is a first- in- man and proof- 
of- concept study with feasibility and safety analysis 
designed to provide preliminary observations and 
generate hypotheses.
 ► Based on the previous literature, the study is consid-
ered positive if the lower boundary of confidence in-
tervals for the feasibility rate in percentage exceeds 
at least 75%, which approximately corresponds to a 
feasibility rate of 84%.
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Ethics and dissemination Each patient has to provide written informed 
consent as approved by the ethical committee of the respective clinical 
site. Results will be submitted for publication in peer- reviewed journals 
and will be disseminated at scientific conferences.
Trial registration number NCT04142021.
INTRODUCTION
Since the introduction of coronary artery bypass grafting 
(CABG), surgical revascularisation has evolved as the 
treatment of choice for patients with complex coronary 
artery disease.1 The extent and complexity of coronary 
artery disease objectively assessed by the anatomical 
Synergy Between percutaneous coronary intervention 
(PCI) With Taxus and Cardiac Surgery (SYNTAX) Score 
combined with clinical characteristics and comorbidities 
play a decisive role when deciding on the revascularisa-
tion strategy.2–5 As a pilot survey of surgeons, the SYNTAX 
III REVOLUTION trial has demonstrated that clinical 
decision- making between CABG and PCI based on coro-
nary CT angiography (CCTA) performed with the high- 
definition GE Healthcare Revolution CT scanner has a 
very high agreement (93% and Cohen’s kappa 0.82) with 
the treatment decision derived from invasive coronary 
angiography (ICA) in patients with three- vessel disease 
with or without left main disease.6
CCTA has emerged as a non- invasive tool able to provide 
an accurate assessment of coronary artery disease even 
in complex lesion subsets.7–10 Physiological assessment 
with fractional flow reserve derived from CT angiography 
(FFR
CT
) has been shown to be accurate in patients with 
multivessel disease.11 Of note, the National Institute for 
Health and Care Excellence in UK has published a guid-
ance on February 2017 recommending coronary CTA 
using HeartFlow FFR
CT
 in patients with recent onset chest 
pain prior to or in replacement of diagnostic test such as 
echocardiography, stress echocardiography, myocardial 
perfusion imaging, stress MRI, CT calcium scoring and 
ICA.12 By adopting this diagnostic approach, the National 
Health Service in England estimates that they will save 
a minimum of £9.1 million by 2022. In the European 
Society of Cardiology guidelines for the diagnosis and 
management of chronic coronary syndrome (CCS), using 
CCTA for the patients with extensive coronary calcifica-
tion, irregular heart rate, significant obesity or inability to 
cooperate with breath- hold commands is described as the 
class III (Is not recommended).13 The limitation of FFR
CT
 
is almost similar to CCTA. However, FFR
CT
 provided high 
and superior diagnostic performance compared with 
CCTA alone in patients and vessels with a high Agaston 
score.14 In addition, the subanalysis of the PACIFIC 
(Prospective Comparison of Cardiac PET/CT, SPECT/
CT Perfusion Imaging and CT Coronary Angiography 
With Invasive Coronary Angiography (PACIFIC) study) 
trial demonstrated that FFR
CT
 showed significantly higher 
diagnostic performance than the others non- invasive tests 
(CCTA, single photon emission CT, and positron emis-
sion tomography) to evaluate ischaemic heart disease 
referenced by invasive FFR.15
European and American guidelines recommend a 
heart team approach (cardiac surgeon, interventional 
cardiologist and cardiologist) for the decision- making 
process between CABG and PCI (class I recommenda-
tion).16 17 The surgeons were part of the multidisciplinary 
heart team that included interventional cardiologists 
and radiologists. During the conduct of the SYNTAX III 
Revolution trial, careful examination and assessment of 
atherosclerotic plaques, including calcium burden and 
interpretation of lesion- specific ischaemia by FFR
CT
, 
prompted the surgeons to raise the hypothesis that CCTA 
coupled with FFR
CT
 might provide sufficient informa-
tion, even superior to ICA in planning CABG.6 However, 
the feasibility and safety of this approach remain to be 
assessed and proved. The aim of the present study is to 
assess the feasibility of CCTA and FFR
CT
 to replace ICA 
as a surgical guidance method for planning and execu-
tion of CABG in patients with three- vessel disease with or 
without left main disease.
METHODS AND ANALYSIS
Study purpose
The study objective is to assess the capability of CCTA to 
replace ICA as a guidance for surgeons in the execution 
of CABG in patients with established three- vessel disease 
with or without left main disease.
Study design
The FASTTRACK CABG study is an investigator- initiated 
single- arm, multicentre, prospective, proof- of- concept, 
and first- in- man study in patients with three- vessel disease 
with or without left main involvement referred to CABG 
treatment. Surgical revascularisation strategy and treat-
ment planning will be solely based on CCTA and FFR
CT
 
without knowledge of the anatomy defined by ICA. The 
ICA will be used in the treatment decision- making process 
(eg, PCI/CABG) by the regular and ‘Conventional Heart 
Team’ which will not be involved in the ‘CCTA Planning 
and Operating Heart Team’ or in the actual surgical treat-
ment (figure 1). One clinical follow- up visit including 
CCTA will be performed at 30 days after CABG in order 
to assess graft patency and topographical adequacy of the 
revascularisation with respect to the surgical planning 
based on non- invasive imaging. Clinical data will be adju-
dicated by an independent Clinical Event Committee. 
Ongoing safety monitoring will be performed by a Data 
Safety Monitoring Board. The flowchart of this study is 
shown in figure 1. Each patient has to provide written 
informed consent as approved by the Ethical Committee 
of the respective clinical site.
Statistical consideration
This is a single- arm safety and feasibility study designed 
to provide preliminary observations and generate 
hypotheses. No formal statistical sample size calculation 
has been performed, however, the feasibility evaluation 
in 100 patients is aimed. In the SYNTAX III Revolution 




 was available in 196/223 patients (88%). 
Taking into consideration a combined potential attri-
tion of CCTA and FFR
CT
 of 12%, 114 patients will be 
included.6 In preparation of this first- in- man study, five 
cardiac surgeons initially involved in the SYNTAX III 
Revolution trial were asked to review retrospectively the 
randomised cases allocated to surgery and to decide on 
an individual basis whether the surgical planning of the 
cases was feasible based on the sole evaluation of CCTA 
and FFR
CT
.18 In this survey, cardiac surgeons agreed in 
84% of cases to plan and perform CABG solely guided 
by the CCTA information including FFR
CT
. It means that 
in 16% of the cases, the surgeon required the viewing of 
ICA. Based on the previous literature, the study is consid-
ered positive if the lower boundary of confidence inter-
vals for the feasibility rate in percentage exceeds at least 
75%, which approximately corresponds to a feasibility 
rate of 84%.19
Primary endpoints
Primary feasibility endpoint is feasibility expressed in 
percentage of CABG planning and execution solely based 
on CCTA in 114 candidates for CABG (ie, the ‘CCTA 
Planning and Operating Heart Team’ and the operator 
being blind for the ICA) (percentage/rate). Primary 
safety endpoint based on 30 day CCTA is the rate of graft 
stenosis (≥50% diameter stenosis (DS) – 99% DS) or 
occlusion (100% DS) either at the ostium, in the shaft 
or at the level of the sequential anastomosis or at the 
distal anastomosis of each individual graft. The primary 
safety endpoint (graft patency) will be evaluated per type 
of graft with respect to historical series of angiographic 
controls performed by ICA or CCTA at 30 days (online 
supplemental file).
Secondary endpoints
Secondary feasibility endpoints include the following: 
(1) CCTA planned revascularisation (anatomic and 
functional) versus the actually executed CABG treat-
ment (topographical adequacy of revascularisation) 
and graft patency of the graft (ie,<50%, ≥50%, ≥75% 
or 100% stenosis); (2) CCTA planned revascularisation 
versus planned revascularisation based on ICA (by non- 
operating surgeons involved in the ‘Conventional Heart 
Team’ based on assessment of ICA performed either in 
the investigational centre or referred from an affiliate 
‘external centre’); (3) planned revascularisation based 
on ICA versus the actually executed revascularisation by 
the investigational centre.
Secondary safety endpoints include the following: 
(1) major adverse cardiac and cardiovascular events at 
hospital discharge and at 30 days: (a) death (all deaths, 
cardiac death, vascular death, cardiovascular death); 
(b) stroke (modified Rankin Scale≥1)20; (c) myocardial 
infarction (MI) according to the Evaluation of XIENCE 
versus Coronary Artery Bypass Surgery for Effectiveness of 
Left Main Revascularization (EXCEL) study definition21; 
(d) all revascularisations (PCI or re- CABG), including 
target vessel and non- target vessel, if applicable; (2) 
need for angiography after CABG procedure prior to the 
30 day follow- up visit due to emergent clinical status; (3) 
bleeding (Bleeding Academic Research Consortium-4); 
(4) procedural complications (online supplemental file); 
(5) other serious adverse events (SAEs); (6) anatomical 
SYNTAX Score calculation based on non- invasive GE 
Healthcare Revolution CT (visual by site and by Academic 
Core Laboratory); (7) functional SYNTAX Score by FFR
CT
 
by Academic Core Laboratory; (8) residual anatomic and 
functional post- CABG SYNTAX Score based on 30 day 
CCTA by Academic Core Laboratory.22
Patient population
One hundred fourteen (114) patients referred for CABG 
will be enrolled in three study sites in Europe and will 
constitute the study population for the feasibility and 
Figure 1 Flowchart. CABG, coronary artery bypass graft; CCTA, coronary CT angiography; FFR
CT
, fractional flow reserve 
derived from CT angiography; ICA, invasive coronary angiography; MIP, maximum intensity projection; MPR, multiplanar 
reconstruction; SYNTAX Score, Synergy Between percutaneous coronary intervention With Taxus and Cardiac Surgery Score.
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safety assessment. The trial was originally intended to take 
place in the four sites including the University Hospital 
of Zurich. However, the trial is no longer going ahead at 
that site due to unforeseen circumstances. By protocol, all 
patients enrolled will be already assigned and referred to 
CABG treatment by the ‘Conventional Heart Team’. All 
sites will be using high- definition GE Healthcare Revolu-
tion CT and HeartFlow FFR
CT
. All diagnostic tools and 
surgical devices used in this study are CE marked, that is, 
are not investigational and are used within intended use.
Inclusion criteria
Inclusion criteria include the following: (1) patients 
referred to CABG treatment (as assessed by ‘Conventional 
Heart Team’) having at the time of the ‘Conventional 
Heart Team’ evaluation at least one de novo stenotic lesion 
(with a visually assessed DS with ≥50%) in all three major 
epicardial territories (left anterior descending (LAD) 
and/or side branch, left circumflex artery (LCX) and/
or side branch, right coronary artery (RCA) and/or side 
branch) supplying viable myocardium with or without left 
main involvement; (2) patients with hypoplastic RCA with 
the absence of descending posterior and presence of a 
lesion in the LAD and LCX territories may be included 
in the trial as three- vessel disease equivalent. Ostial LAD 
plus ostial LCX may be included in the trial as a left 
main equivalent; (3) distal vessel size should be at least 
1.5 mm in diameter as visually assessed in the diagnostic 
angiogram (as requested by the surgeons); (4) patients 
with silent ischaemia, CCS or stabilised acute coronary 
syndrome with normalised (stable or decreasing) cardiac 
biomarker values. For patients showing elevated cardiac 
troponin (eg, non- ST elevation MI patients) at baseline 
(within 24 hours pre- CABG) an additional blood sample 
must be collected prior to CABG to confirm that: (a) high- 
sensitivity cardiac troponin (hs- cTn) or troponin I or T 
levels are stable, that is, the value should be within 20% 
range of the value found in the first sample at baseline, or 
have dropped23; (b) creatine kinase- muscle/brain (CK- 
MB) and CK levels are within normal range. If hs- cTn or 
troponin I or T levels are stable or have dropped, or the 
CK- MB and CK levels are within normal ranges and the 
ECG is normal, patients may be included in the study; (5) 
all anatomical SYNTAX Scores are eligible; (6) patients 
are amenable to CCTA (eg, no claustrophobia, high heart 
rate not amenable to beta- blockers, poor renal function, 
etc., up to the discretion of the investigator); (7) patients 
have been informed of the nature of the study and agree 
to its provisions and have provided written informed 
consent as approved by the Ethical Committee of the 
respective clinical site; (8) patients agree to 1 month 
follow- up visit including CCTA.
Exclusion criteria
Candidates will be ineligible for enrolment in the study 
if any of the following conditions apply: (1) under the 
age of 18 years; (2) unable to give informed consent; 
(3) known pregnancy at the time of enrolment; female 
of childbearing potential, that is, who are not surgically 
sterile or post- menopausal (defined as no menses for 2 
years without an alternative cause); female who is breast-
feeding at time of enrolment; (4) prior PCI or CABG; 
history of coronary stent implantation; (5) evidence of 
evolving or ongoing ST- elevation MI on ECG and/or 
elevated cardiac biomarkers (according to local standard 
hospital practice) have not returned within normal limits 
at the time of enrolment (non- ST elevation MI); (6) 
known renal insufficiency (eg, serum creatinine >2.5 mg/
dL, or creatinine clearance ≤30 mL/min), or need for 
dialysis, or acute kidney failure (as per physician judge-
ment); (7) concomitant cardiac valve disease requiring 
surgical therapy (repair or replacement) and/or aneurys-
mectomy; (8) single or two- vessel disease (at time of the 
conventional heart team consensus); (9) non- graftable 
distal bed in >1 vessel as assessed by the surgeon based 
on ICA; (10) persistent atrial fibrillation or significant 
arrhythmias; (11) known allergy to iodinated contrast; 
(12) a body mass index of 35 or greater; (13) currently 
participating in another clinical trial not yet at its primary 
endpoint.
CCTA acquisition
Initial diagnostic screening for assessment of multivessel 
disease with or without left main involvement may be 
performed by either ICA or CCTA (if standard of care). 
Whenever CCTA is not available or when the quality of 
the initial diagnostic CCTA is suboptimal, CCTA must 
be obtained/repeated using the 256- slice GE Healthcare 
Revolution CT scanner and the acquisition should be 
optimal according to acquisition protocol (online supple-
mental file). In case a patient had already undergone a 
GE Healthcare Revolution CT for clinical reasons prior 
to study start (ie, within 1 month prior to enrolment) 
but without scanning of the origin and proximal part of 
mammary arteries (left internal mammary artery/right 
internal mammary artery), additional CCTA imaging of 
the mammary arteries could be performed according to 
the request of the surgeon and according to local prac-
tice, to either: (a) add a dedicated small scan for the 
mammary arteries (if the previous ‘clinical’ CCTA has 
been obtained with GE Healthcare Revolution CT and 
is acquired according to the acquisition protocol) or (b) 
redo the entire scan, that is, mammary arteries plus coro-
nary arteries (in case the image quality of the previous scan 
is not adequate according to the acquisition protocol). A 
patient who does not have an evaluable CCTA at baseline 
(according to the Academic Core Laboratory assessment) 
will be defined as a ‘screen failure’.
Academic core laboratory
The reconstructed CCTA images should be transferred 
electronically to the independent Academic Core Labo-
ratory and to HeartFlow (Redwood City, California, USA) 
for FFR
CT
. CCTA imaging data will also be provided to GE 
Healthcare for general assessment of CT exams. Sites may 
store raw CCTA data for a period of 5 years for additional 
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exploratory analysis ensuring confidentiality of personal 
data. The anatomical SYNTAX Score by CCTA will be 
performed by the Academic Core Laboratory. The heart 
team will consult the Academic Core Laboratory SYNTAX 
Score during the ‘CCTA Planning and Operating Heart 
Team’ meeting whenever deemed necessary. The ‘CCTA 
Planning and Operating Heart Team’ will also receive, 
from the Academic Core Laboratory for consultation, the 
SYNTAX Score III that is the combination of the anatomic 
SYNTAX Score, functional SYNTAX Score and comor-
bidities (figures 2 and 3). If the Academic Core Labora-
tory judges that the quality of the CCTA is not sufficient, 
the CT images may be reconstructed and sent again for 
assessment of quality.
Heart team
The ‘Conventional Heart Team’ consists of at least one inter-
ventional cardiologist and one cardiac surgeon (figure 1). 
Figure 2 Calculation of functional SYNTAX Score. The functional SYNTAX Score uses the principle of the functional 
assessment of coronary lesions derived from FFR
CT
, as is undertaken in conventional anatomical SYNTAX Score calculation. 
If intermediate stenotic lesions are identified anatomically, but not confirmed as functionally significant, the weighted score 
of that anatomic segment is subtracted from the functional SYNTAX Score which is combined with the clinical characteristics 
and comorbidities of the patients to generate the SYNTAX Score III (an integrated indicator of the risk and benefit of 
revascularisation). SYNTAX Score: Synergy Between percutaneous coronary intervention With Taxus and Cardiac Surgery 
Score, FFR
CT
: fractional flow reserve derived from CT angiography; LAD, left anterior descending; LCX, left circumflex artery; 
RCA, right coronary artery.
Figure 3 Anatomic SYNTAX Score and functional SYNTAX Score. In this case, anatomical SYNTAX Score is 40.5 point and 
functional SYNTAX Score is 24.5 points after the calculation (subtraction of the non- physiological stenotic vessel segment 




, fractional flow reserve derived from CT angiography; SYNTAX Score: Synergy Between 
percutaneous coronary intervention With Taxus and Cardiac Surgery Score.
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The ‘Conventional Heart Team’ can be located and opera-
tional inside (internal referral) or outside (external referral) 
the investigational sites. The ‘Conventional Heart Team’ is 
fully independent of the ‘CCTA Planning and Operating 
Heart Team’ and study staff, and the clinical contribution 
of its members will be acknowledged in the appendix of 
future publications. Planning of the CABG procedure during 
‘Conventional Heart Team’ based on ICA will be performed 
by a cardiac surgeon, blind to the CCTA result and not 
involved in the ‘CCTA Planning and Operating Heart Team’. 
The ‘CCTA Planning and Operating Heart Team’ consists of 
a cardiac surgeon, a radiologist (experienced CCTA reader) 
and a research nurse/study coordinator (figure 1). It is essen-
tial that the ‘CCTA Planning and Operating Heart Team’, 
who is judging the CCTA, is blind to ICA.
CCTA planning and operating heart team: structure and 
organisation
The ‘CCTA Planning and Operating Heart Team’ meeting 
should only start when all information is available and 
accessible, that is, anatomic SYNTAX Score (by site and by 
Academic Core Laboratory), and FFR
CT
. The investigator 
must confirm in the electronic case report form (eCRF) that 
all scores/reports (gender, age, peripheral vessel disease, 
chronic obstructive pulmonary disease, creatinine clearance 
and anatomical and functional SYNTAX Score) have been 
reviewed prior to ‘CCTA Planning and Operating Heart 
Team’ meeting. The CABG procedure has to be executed 
by the cardiac surgeon or one of his delegated collaborators 
who have participated in the ‘CCTA Planning and Operating 
Heart Team’ or are fully informed about the surgical plan-
ning of the ‘CCTA Planning and Operating Heart Team’. 
Any deviation from the surgical planning has to be docu-
mented in the eCRF.
Preparation of CABG treatment by means of CCTA
The radiologist (or experienced CCTA reader) of the ‘CCTA 
Planning and Operating Heart Team’ meeting will confirm 
the anatomical SYNTAX Score. As an external reference, 
the independent Academic Core Laboratory also provides 
anatomical SYNTAX Score on CCTA for consultation and 
calculates the functional SYNTAX Score by subtracting from 
the anatomic SYNTAX Score weighted, points of non- flow 
limiting lesions (>0.80), normally attributed to the weighted 
automatic lesions (incremental value FFR
CT
)14 and SYNTAX 
Score III (=merging of functional SYNTAX Score with 
comorbidities).
CABG procedure
The CABG procedure will be performed according to local 
standards.24 Post- CABG, the following data will be collected 
in the eCRF (actual treatment): (a) number of diseased 
vessels/diseased lesions; (b) diseased segment number; (c) 
number and location of anastomoses; (d) type of bypass graft 
(mammary artery, radial, saphenous vein, other) (online 
supplemental file, online supplemental video 1); (e) type of 
grafting: end- to- side (end of the conduit graft to the side of 
the coronary artery) or side- to- side (sequential, jump graft, 
or Y- graft). In addition to the actual treatment, only limited 
details about the CABG procedure will be collected in the 
eCRF (eg, adjunctive pharmacological treatment, total oper-
ation time, clamping time, procedural details (off- pump or 
on- pump procedure), type of cardioplegia and procedural 
complications according to the protocol of the EXCEL study 
(online supplemental file).25
Follow-up
Patient will undergo a CCTA 30 days (±7 days) after CABG 
in order to judge the patency and adequacy of revasculari-
sation.26 The follow- up CCTA will be sent to the Academic 
Core Laboratory as instructed for analysis. An assessment 
of the anginal status, cardiovascular drug use and any SAE 
will be recorded, moreover, a standard 12- lead ECG will be 
performed at the 30 days follow- up visit. These information 
will be collected in the eCRF.
Patients and public involvement
The FASTTRACK CABG trial is a feasibility study without 
powered clinical/imaging endpoint. If this feasibility study is 
positive, then subsequent studies on this topic will be planned 
to demonstrate the clinical and economical benefit. Due to 
the nature of the feasibility study, involvement of patient 
and public is limited to sharing the results of the study after 
completion of study follow- up.
Ethics and dissemination
Ethical approvals from the ethics committee of the Centro 
Cardiologico Monzino (R1158/20- CCM 1220), Univer-
sity Hospital of Brussels (B1432020000236) and University 
Hospital of Jena (2020-1889-1- BO) have been obtained. Each 
patient has to provide written informed consent as approved 
by the ethical committee of the respective clinical site. Results 
will be submitted for publication in peer- reviewed journals 
and will be disseminated at scientific conferences.
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